专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240002495A1 HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY 审中-公开
公开(公告)号：US20240002495A1
公开(公告)日：2024-01-04
申请号：US18340790
申请日：2023-06-23
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/244 , A61K39/39591 , A61K2039/505
摘要： An antibody has an antagonistic effect against IL-33. An isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

2. 发明申请

US20160289322A1 HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY 有权
标题翻译：人类抗IL-33中和性单克隆抗体
公开(公告)号：US20160289322A1
公开(公告)日：2016-10-06
申请号：US15037998
申请日：2014-12-26
申请人： MITSUBISHI TANABE PHARMA CORPORATION
发明人： Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A61K39/39591 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.
摘要翻译：本发明的目的是提供对IL-33具有拮抗作用的抗体，特别是分离的人抗IL-33中和单克隆抗体，其中构架区的氨基酸序列是氨基酸序列，种系或其氨基酸序列的组合，或其片段。鉴定出多种抗IL-33单克隆抗体的表位，获得人抗IL-33中和单克隆抗体，通过在IL-33中引入突变来指定实现对IL-33的高结合能力的互补决定区互补决定区域。所鉴定的互补决定区用于产生具有包含作为种系的氨基酸序列或其氨基酸序列的组合的氨基酸序列的构架区的人抗IL-33中和单克隆抗体。

3. 发明授权

US09758578B2 Human anti-IL-33 neutralizing monoclonal antibody 有权
公开(公告)号：US09758578B2
公开(公告)日：2017-09-12
申请号：US15037998
申请日：2014-12-26
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
IPC分类号： C07K16/24 , A61K39/395 , A61K39/00
CPC分类号： C07K16/244 , A61K39/39591 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.

4. 发明授权

US09725508B2 Human anti-IL-33 neutralizing monoclonal antibody 有权
公开(公告)号：US09725508B2
公开(公告)日：2017-08-08
申请号：US15037998
申请日：2014-12-26
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
IPC分类号： C07K16/24 , A61K39/395 , A61K39/00
摘要： An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.

5. 发明申请

US20170283494A1 HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY 审中-公开
公开(公告)号：US20170283494A1
公开(公告)日：2017-10-05
申请号：US15621950
申请日：2017-06-13
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/244 , A61K39/39591 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

6. 发明授权

US11725049B2 Human anti-IL-33 neutralizing monoclonal antibody 有权
公开(公告)号：US11725049B2
公开(公告)日：2023-08-15
申请号：US16414602
申请日：2019-05-16
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
IPC分类号： C07K16/24 , A61K39/395 , A61K39/00
CPC分类号： C07K16/244 , A61K39/39591 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

7. 发明申请

US20190330329A1 HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY 审中-公开
公开(公告)号：US20190330329A1
公开(公告)日：2019-10-31
申请号：US16414602
申请日：2019-05-16
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
IPC分类号： C07K16/24 , A61K39/395
摘要： An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式